|
TG Therapeutics, Inc. (TGTX) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
TG Therapeutics, Inc. (TGTX) Bundle
Möchten Sie den inneren Wert von TG Therapeutics, Inc. bewerten? Unser TGTX DCF-Taschenrechner integriert reale Daten mit umfangreichen Anpassungsoptionen, sodass Sie Ihre Prognosen verfeinern und Ihre Anlagestrategien verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .2 | .2 | 6.7 | 2.8 | 233.7 | 316.4 | 428.4 | 580.1 | 785.6 | 1,063.7 |
| Revenue Growth, % | 0 | 0 | 4300.66 | -58.36 | 8290.02 | 35.41 | 35.41 | 35.41 | 35.41 | 35.41 |
| EBITDA | -168.5 | -272.7 | -342.0 | -187.6 | 26.1 | -246.1 | -333.2 | -451.1 | -610.9 | -827.2 |
| EBITDA, % | -110856.58 | -179393.42 | -5112.41 | -6737.13 | 11.17 | -77.77 | -77.77 | -77.77 | -77.77 | -77.77 |
| Depreciation | .3 | .4 | .5 | .5 | .4 | 143.0 | 193.7 | 262.3 | 355.2 | 480.9 |
| Depreciation, % | 185.53 | 246.05 | 7.39 | 18.49 | 0.18103 | 45.21 | 45.21 | 45.21 | 45.21 | 45.21 |
| EBIT | -168.8 | -273.1 | -342.5 | -188.1 | 25.7 | -246.2 | -333.3 | -451.4 | -611.2 | -827.6 |
| EBIT, % | -111042.11 | -179639.47 | -5119.79 | -6755.62 | 10.99 | -77.8 | -77.8 | -77.8 | -77.8 | -77.8 |
| Total Cash | 140.4 | 605.4 | 350.3 | 174.1 | 217.5 | 312.0 | 422.5 | 572.1 | 774.7 | 1,049.0 |
| Total Cash, percent | .1 | .4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 1.4 | .0 | 51.1 | 27.0 | 36.5 | 49.5 | 67.0 | 90.7 |
| Account Receivables, % | 0 | 0 | 20.77 | 0 | 21.87 | 8.53 | 8.53 | 8.53 | 8.53 | 8.53 |
| Inventories | .0 | .0 | -23.6 | .0 | 39.8 | -52.5 | -71.1 | -96.3 | -130.3 | -176.5 |
| Inventories, % | 0 | 0 | -352.88 | 0 | 17.04 | -16.59 | -16.59 | -16.59 | -16.59 | -16.59 |
| Accounts Payable | 30.0 | 37.0 | .0 | 42.0 | 38.5 | 200.3 | 271.2 | 367.2 | 497.2 | 673.3 |
| Accounts Payable, % | 19763.82 | 24351.32 | 0 | 1508.76 | 16.46 | 63.29 | 63.29 | 63.29 | 63.29 | 63.29 |
| Capital Expenditure | -.1 | -.4 | -.4 | .0 | .0 | -121.9 | -165.1 | -223.6 | -302.7 | -409.9 |
| Capital Expenditure, % | -86.18 | -234.87 | -5.99 | -0.50269 | 0 | -38.54 | -38.54 | -38.54 | -38.54 | -38.54 |
| Tax Rate, % | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 |
| EBITAT | -175.1 | -279.4 | -349.8 | -193.4 | 24.9 | -244.7 | -331.3 | -448.7 | -607.5 | -822.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -144.9 | -272.4 | -364.5 | -173.1 | -69.1 | 54.6 | -222.8 | -301.7 | -408.5 | -553.2 |
| WACC, % | 14.62 | 14.62 | 14.62 | 14.62 | 14.61 | 14.62 | 14.62 | 14.62 | 14.62 | 14.62 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -838.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -564 | |||||||||
| Terminal Value | -4,472 | |||||||||
| Present Terminal Value | -2,261 | |||||||||
| Enterprise Value | -3,100 | |||||||||
| Net Debt | 18 | |||||||||
| Equity Value | -3,118 | |||||||||
| Diluted Shares Outstanding, MM | 149 | |||||||||
| Equity Value Per Share | -20.99 |
What You Will Get
- Real TG Therapeutics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on TG Therapeutics’ fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Customizable Clinical Parameters: Adjust essential metrics such as pipeline progress, market potential, and R&D expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- High-Precision Analysis: Utilizes TG Therapeutics' actual financial data for accurate valuation results.
- Effortless Scenario Testing: Evaluate various assumptions and assess different outcomes with ease.
- Efficiency Booster: Avoid the complexities of creating intricate valuation models from the ground up.
How It Works
- Download: Obtain the pre-built Excel file featuring TG Therapeutics, Inc. (TGTX) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and compare results instantly.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose TG Therapeutics, Inc. (TGTX)?
- Innovative Treatments: Focused on developing novel therapies for patients with hematologic malignancies and autoimmune diseases.
- Strong Pipeline: A robust pipeline of drug candidates targeting unmet medical needs.
- Expert Team: Led by experienced professionals with a proven track record in biotechnology.
- Commitment to Patients: Dedicated to improving patient outcomes through cutting-edge research and development.
- Proven Results: Backed by clinical data demonstrating the efficacy of our therapies.
Who Should Use TG Therapeutics, Inc. (TGTX)?
- Investors: Gain insights into the potential of innovative therapies backed by robust research.
- Healthcare Analysts: Streamline your analysis with detailed reports on drug development and market trends.
- Pharmaceutical Consultants: Tailor materials for client engagements with up-to-date information on TG Therapeutics' pipeline.
- Biotech Enthusiasts: Enhance your knowledge of the biotechnology sector through case studies and real-world applications.
- Educators and Students: Utilize it as a resource for learning about drug development and market dynamics in pharmaceutical studies.
What the Template Contains
- Pre-Filled DCF Model: TG Therapeutics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate TG Therapeutics’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.